A. Marchesoni1, I. Olivieri2, C. Salvarani3, N. Pipitone4, S. D'Angelo5, A. Mathieu6, A. Cauli7, L. Punzi8, R. Ramonda9, R. Scarpa10, M. Maccarone11, E. Lubrano12
2017 Vol.35, N°6 - PI 0991, PF 1010
To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA).
To create this new set of recommendations, the SIR “Spondyloartritis and Psoriatic Arthritis study group – A. Spadaro” went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations.
An update on the available evidence on all of the biologics and new small molecules tested in PsA is reported, comprising the data for each of the individual articular manifestation. Indications for therapy inclusion criteria, choice of the drug, disease assessment, response definition, therapy failure management, and disease remission management for PsA peripheral joint arthritis, enthesitis, dactylitis, and spondylitis are provided. Suggestions for the treatment of patients with PsA and concomitant extra-articular manifestations are also given.
These evidence-based recommendations may be used for guidance in the complex and fast-evolving field of the treatment of PsA.
PMID: 29185959 [PubMed]
Received: 09/05/2017 - Accepted : 02/08/2017 - In Press: 28/11/2017 - Published: 12/12/2017